The PREDIMED Trial: How Extra Virgin Olive Oil Reduced Cardiovascular Events by 31%

In nutritional science, few studies have the power to shift clinical practice. The PREDIMED trial — Prevención con Dieta Mediterránea — is one of them. Conducted across multiple centres in Spain, enrolling 7,447 participants at high cardiovascular risk and following them for a median of 4.8 years, PREDIMED remains the largest and most rigorous dietary intervention study for cardiovascular disease prevention ever completed. Its findings established the Mediterranean diet with extra virgin olive oil as one of the most evidence-backed dietary approaches to heart health in medical history.

The PREDIMED Study Design

Participants were adults aged 55–80 (men) or 60–80 (women) with either type 2 diabetes or at least three major cardiovascular risk factors (smoking, hypertension, elevated LDL, low HDL, overweight/obesity, or family history of premature heart disease). None had diagnosed cardiovascular disease at enrolment — this was a primary prevention trial.

Participants were randomly assigned to one of three dietary interventions:

1. Mediterranean diet + extra virgin olive oil: approximately 4 tablespoons (50mL) of EVOO daily
2. Mediterranean diet + mixed nuts: 30g daily (walnuts, almonds, hazelnuts)
3. Control diet: advice to reduce all dietary fat (low-fat diet)

The primary endpoint was a composite of major cardiovascular events: myocardial infarction, stroke, or cardiovascular death.

The Results

The trial was stopped early — before its planned completion — because the interim analysis showed such significant benefits in the two Mediterranean diet groups that continuing to withhold the intervention from control participants was considered ethically unjustifiable.

The key findings published in the New England Journal of Medicine (2013, with a correction and republication in 2018):

• Mediterranean diet + EVOO: 31% relative risk reduction in major cardiovascular events compared to the low-fat control diet (hazard ratio 0.69, 95% CI 0.53–0.91)
• Mediterranean diet + nuts: 28% relative risk reduction (hazard ratio 0.72, 95% CI 0.54–0.96)
• The EVOO group showed particularly strong protection against stroke — with a 39% relative risk reduction, one of the largest stroke risk reductions ever demonstrated in a dietary trial

These effect sizes are clinically substantial. For comparison, statin therapy reduces cardiovascular events by approximately 25–35% in high-risk patients — and the PREDIMED EVOO arm matched this benchmark through dietary modification alone.

PREDIMED Substudies: Additional Findings

The PREDIMED cohort generated numerous substudies examining specific outcomes beyond the primary cardiovascular endpoint:

Diabetes Prevention

A PREDIMED substudy published in Diabetes Care found that participants in the Mediterranean diet + EVOO group had a 40% lower incidence of new-onset type 2 diabetes compared to the control group over the study period. A meta-analysis of four cohorts and 29 trials subsequently confirmed that EVOO intake of 15–20g/day is associated with a 13% reduction in diabetes risk — an effect attributed to improved insulin sensitivity and glucose metabolism through EVOO polyphenol activity.

Cognitive Function

A PREDIMED-NAVARRA substudy assessed cognitive function in a subset of participants and found the Mediterranean diet + EVOO group showed significantly better Mini-Mental State Examination scores and composite cognitive function compared to the control group after 6.5 years of follow-up. This cognitive protection aligns with EVOO's independent neurological evidence base (covered separately).

Atrial Fibrillation

A substudy found Mediterranean diet with EVOO was associated with a 38% lower incidence of atrial fibrillation — a major risk factor for stroke — compared to the low-fat control diet. This is one of the first large-scale dietary trial findings for atrial fibrillation prevention.

Cancer Mortality

An 8-year follow-up analysis found participants in the Mediterranean diet + EVOO group had significantly lower cancer mortality, with the association strongest for breast cancer. A meta-analysis of 19 observational studies (13,800 patients, 23,340 controls) confirmed olive oil intake is inversely associated with cancer prevalence.

The 2025 Systematic Review Confirmation

A 2025 systematic review published in Nutrients (Ussia et al., from five Italian university medical centres) reviewed all RCT evidence from 2005–2025 on EVOO supplementation and cardiovascular disease. The review confirmed across all included trials: improvements in LDL oxidation resistance, endothelial function (measured by flow-mediated dilation), inflammatory biomarkers (CRP, TNF-alpha), and lipid profiles — with the beneficial effects consistently and specifically attributed to the polyphenol content of EVOO rather than its monounsaturated fat component. Refined olive oil with equivalent fatty acid composition but without polyphenols consistently showed smaller or no measurable cardiovascular effects in head-to-head comparisons.

Mechanisms Behind the Cardiovascular Benefit

The PREDIMED results are explained by a convergence of EVOO's multiple cardiovascular-active mechanisms:

• LDL oxidation prevention: Oleocanthal and hydroxytyrosol prevent the oxidation of LDL particles — the initiating step in atherosclerotic plaque formation. One year of EVOO-enriched Mediterranean diet significantly enhanced LDL resistance to oxidation in PREDIMED participants compared to low-fat diet.
• Endothelial function: EVOO polyphenols increase nitric oxide bioavailability in arterial endothelium, improving vasodilation and blood pressure regulation. A crossover RCT found a single 50mL dose of high-polyphenol EVOO significantly improved endothelial function (measured by FMD) compared to refined oil.
• Anti-inflammatory activity: COX inhibition by oleocanthal, NF-kB inhibition by hydroxytyrosol, and downstream reductions in CRP, IL-6, and TNF-alpha reduce the chronic vascular inflammation that drives atherosclerosis progression.
• Platelet aggregation inhibition: EVOO polyphenols reduce thromboxane B2 — a pro-thrombotic eicosanoid — and inhibit ADP-induced platelet aggregation, reducing thrombotic cardiovascular event risk.
• HDL functionality improvement: High-polyphenol EVOO increases both HDL concentration and HDL functionality (reverse cholesterol transport capacity), improving the ratio of protective to atherogenic cholesterol.

How Much EVOO Do You Need?

The PREDIMED EVOO group consumed approximately 50mL (4 tablespoons) daily — a substantial daily dose that was integral to the Mediterranean diet pattern. However, the cardiovascular biomarker evidence suggests meaningful benefit at lower doses:

• 15–20g/day (1–1.5 tablespoons): The diabetes prevention threshold identified in meta-analysis
• 25–30g/day (2 tablespoons): Sufficient for LDL oxidation protection and measurable endothelial improvements in most trials
• 50mL/day (4 tablespoons): The PREDIMED dose producing the most robust cardiovascular event reduction

Polyphenol content matters at every dose level. 50mL of high-polyphenol EVOO (≥400mg/kg) delivers approximately 20–25mg total polyphenols — a dose consistently above the EFSA qualifying threshold. 50mL of a low-polyphenol oil (50mg/kg) delivers only 2.5mg — a 10-fold difference in bioactive content for the same caloric intake.